CytoCore’s SoftPap
This article was originally published in The Gray Sheet
Executive Summary
Cancer screening test firm CytoCore receives 510(k) clearance for its SoftPap cervical cell collector Jan. 30 and plans to sign its first U.S. distribution agreements in the coming days for launch by the end of March, the firm said Feb. 5. SoftPap consists of a reusable handle and disposable balloon, which inflates inside the body to collect cervical cells. CytoCore says the system collects better samples than the alternative spatula and brush collection method, and could be used with Cytyc/Hologic's ThinPrep liquid-based Pap test and BD/TriPath's SurePath test. The device will cost $10-$12 out-of-pocket, compared to less than $1 for the reimbursed brush technique, but will "more than prove to be cost-effective," marketing director Dan McMahon claims. SoftPap has been sold in Europe since late December
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.